Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL2482060 | 1.00 | KMT2A (0.70) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL22501358 | 1.00 | KMT2A (0.70) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL6691598 | 1.00 | KMT2A (0.70) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL16914545 | 0.95 | KMT2A (0.63) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL15017859 | 0.95 | KMT2A (0.63) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL28025692 | 0.95 | KMT2A (0.63) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL25307133 | 0.93 | KMT2A (0.61) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL6130109 | 0.93 | ALOX15 (0.61) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL22501364 | 0.93 | KMT2A (0.61) | KMT2APMP22ALOX15BLMCYP1A2 | |
| Glutamine SCHEMBL29060080 | 0.93 | KMT2A (0.61) | KMT2APMP22ALOX15BLMCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220192179-A1 | BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2022-06-23 | — | — | US | claimed |
| CN-102245208-B | immunoglobulin variants and uses thereof | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-16 | — | — | CN | claimed |
| US-20210190785-A1 | Biomarkers for Assessing Breast Cancer | BIOCRATES LIFE SCIENCE AG (AT) | 2021-06-24 | — | — | US | disclosed |
| US-10962542-B2 | Biomarkers for assessing breast cancer | Metabolomycs, Inc. | 2021-03-30 | — | — | US | disclosed |
| US-20200362046-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC | 2020-11-19 | — | — | US | disclosed |
| CN-110462038-A | Anti- GPRC5D antibody and the molecule comprising the antibody | DAIICHI SANKYO CO LTD | 2019-11-15 | — | — | CN | disclosed |
| US-10456736-B2 | Method and apparatus for purification and treatment of air | PALOZA LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3191845-B1 | BIOMARKERS FOR ASSESSING BREAST CANCER | IDCGS CLINICA DE DIAGNOSTICOS MEDICOS LTDA (BR) | 2019-10-23 | — | — | EP | disclosed |
| CN-105637366-B | Detection method, antibody and the pancreas lesion detection kit of pancreas tumour | 东丽株式会社 | 2018-05-29 | — | — | CN | disclosed |
| US-20170299592-A1 | BIOMARKERS FOR ASSESSING BREAST CANCER | METABOLOMYCS, INC | 2017-10-19 | — | — | US | disclosed |
| CN-107076748-A | Assess the biomarker of breast cancer | IDCGS临床诊断医疗有限公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2013004710-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| EP-2377881-A2 | Clostridial toxin activatable clostridial toxins | Allergan, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20090019609-A1 | Expression of Cry3B Insecticidal Protein in Plants | ROMANO CHARLES P | 2009-01-15 | — | — | US | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-6803203-B1 | PROTEIN KINASES; FOR MONITORING IN VITRO ACTIVITY IN EUKARYOTIC CELLS; DRUG SCREENING; KITS | BROOKHAVEN SCIENCE ASSOCIATES | 2004-10-12 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
| US-6298858-B1 | Tobacco flavoring components of enhanced aromatic content and method of providing same | R. J. REYNOLDS TOBACCO COMPANY | 2001-10-09 | — | — | US | disclosed |
| WO-2000028840-A1 | TOBACCO FLAVORING COMPONENTS OF ENHANCED AROMATIC CONTENT AND METHOD OF PROVIDING SAME | R. J. REYNOLDS TOBACCO COMPANY (US) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192179-A1 | BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME | IGFBP1, IGFBP2, BCL2L1 | KMT2A 4430/4885PMP22 64/4885ALOX15 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.